Home LiteratureArticle Details
PMID: 15901872 Published · ppublish English Letter Comment

EGFR mutation and response of lung cancer to gefitinib.

The New England journal of medicine ·Vol. 352 ·No. 20 ·2005-05-19 ·Pages 2136; author reply 2136

Toyooka S, Kiura K, Mitsudomi T

Abstract

暂无摘要

MeSH Terms
Antineoplastic Agents/therapeutic use Carcinoma, Non-Small-Cell Lung/drug therapy,genetics Drug Resistance, Neoplasm/genetics ErbB Receptors/genetics Female Gefitinib Genotype Humans Lung Neoplasms/drug therapy,genetics Point Mutation Quinazolines/therapeutic use
Chemicals
Antineoplastic Agents Quinazolines ErbB Receptors Gefitinib
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Toyooka Shinichi
Kiura Katsuyuki
Mitsudomi Tetsuya
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
DOI
10.1056/NEJM200505193522019
Published
2005-05-19
Pages
2136; author reply 2136
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentOn
PMID: 15728811
External Links
PubMed source DOI: 10.1056/NEJM200505193522019 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2